Teduglutide
| Evidence Level: L4 | Predicted Indications: 10 |
Table of Contents
Teduglutide: From Short Bowel Syndrome to Chronic Intestinal Vascular Insufficiency
One-Sentence Summary
Teduglutide is a GLP-2 receptor agonist whose established therapeutic role centers on short bowel syndrome (SBS)-associated intestinal failure, where it promotes intestinal mucosal growth and absorptive capacity. The TxGNN model predicts potential relevance to Chronic Intestinal Vascular Insufficiency, a mechanistically plausible extension of its known trophic and blood-flow effects on the gut, but this direction is currently supported only by 1 indirect review article and no clinical trials.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Short bowel syndrome (SBS)-associated intestinal failure (derived from mechanistic rationale in the Evidence Pack; not from a formal EU authorization record) |
| Predicted New Indication | Chronic Intestinal Vascular Insufficiency |
| TxGNN Prediction Score | 92.22% |
| Evidence Level | L4 |
| EU Market Status | Not marketed |
| Number of Authorizations | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
A formal mechanism-of-action record is not available in the Evidence Pack (original_moa: Data Gap). However, the drug-level rationale accompanying the predictions consistently describes teduglutide as a GLP-2 receptor agonist that promotes intestinal mucosal proliferation, increases villus height and crypt depth, and enhances intestinal blood flow and absorptive surface area — the mechanistic basis for its established role in SBS-related intestinal failure.
Chronic intestinal vascular insufficiency shares pathophysiological overlap with short bowel/intestinal adaptation disorders, since both involve compromised mucosal integrity and regional blood flow in the gut. Teduglutide’s known effect of increasing intestinal blood flow provides a theoretical rationale for benefit in this setting. That said, the only supporting reference identified is a general review of SBS pharmacotherapy — it does not directly study chronic intestinal vascular insufficiency, so the mechanistic link remains inferential rather than confirmed.
It is also worth noting that several other TxGNN-ranked predictions in this Evidence Pack — including papillary conjunctivitis (the top-scored prediction, 98.5%), gastroduodenitis, peptic ulcer disease, nasal cavity disease, acute laryngopharyngitis, allergic urticaria, pharyngitis, and atopic conjunctivitis — were reviewed against known GLP-2 biology and explicitly flagged in the source rationale as lacking a credible mechanistic basis (e.g., no known GLP-2 receptor expression in ocular, nasal, or upper-respiratory tissue). These are assessed as likely model noise and are not carried forward as viable repurposing candidates in this report.
Clinical Trial Evidence
Currently no related clinical trials registered
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 32057270 | 2020 | Review | Expert Opinion on Pharmacotherapy | Reviews pharmacotherapy options for short bowel syndrome, including GLP-2-based agents like teduglutide that target disease pathophysiology; does not directly study chronic intestinal vascular insufficiency |
EU Market Information
This drug is currently marked as not marketed in the covered EU dataset, with no authorization records available (total_licenses: 0). Note: this status should be independently verified against current EU regulatory sources, as it may reflect a data gap rather than actual market absence.
Safety Considerations
Please refer to the SmPC for safety information.
Additionally, the Evidence Pack flags a Blocking data gap (DG001): official label warnings and contraindications are not yet available, which prevents this candidate from entering the S1 safety pre-assessment stage.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication is mechanistically plausible but supported only by a single indirect review article (L4, no direct clinical trials), and a blocking data gap prevents formal safety pre-assessment. This corresponds to a “Research Question” stage rather than an actionable repurposing candidate.
To proceed, the following is needed:
- Official label warnings and contraindications (SmPC/regulatory label) to complete the S1 safety screening
- Confirmed detailed mechanism-of-action documentation (e.g., from DrugBank)
- Direct clinical or preclinical evidence specifically evaluating teduglutide in chronic intestinal vascular insufficiency
- Verification of current EU marketing authorization status, as the “not marketed” flag in this dataset should be reconciled with primary regulatory sources
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.